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ABSTRACT
Objectives: This study assesses the cost-effectiveness of sacubitril/valsartan versus enalapril in patients
with symptomatic heart failure with reduced ejection fraction (HFrEF).
Methods: We used a previously developed Markov model calibrated with patient-level data from the
PARADIGM-HF trial, adapted to the Portuguese setting. The model considers two health states (alive or
dead) and uses regression analyzes to estimate hospitalizations and deaths over time. A panel of experts
estimated resource consumption in the outpatient setting. To estimate resource consumption with hospita-
lizations, the National Health Service Diagnosis Related Groups database was used. Unit costs were based on
national legislation, and on the Infomed database. The model considers a societal perspective, a time horizon
of 30-years, and a 5% annual discount rate. Sensitivity analyses assessed the robustness of results.
Results: Sacubitril/valsartan increases life expectancy by 0.5 life-years, corresponding to 0.4 incremental
quality adjusted life-years (QALY) versus enalapril. The estimated incremental cost-effectiveness ratio
(ICER) is 22,702€/QALY. Sensitivity analysis shows that results are robust, but sensitive to the parameter
estimates of the cardiovascular survival curve.
Conclusion: Sacubitril/valsartan is a cost-effective therapeutic option in the treatment of Portuguese
patients with HFrEF and translate into significant health gains and increased life expectancy versus the
current standard of care.
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1. Introduction
Heart failure (HF) is widely acknowledged as a global public
health problem with high impact on patients’ quality of life
(QoL), hospitalizations, and mortality [1,2].
The analysis of published international epidemiological data
suggests an increase in the prevalence of HF in recent decades
[3–5]. A Portuguese epidemiologic study published in 1998 (the
EPICA study) estimated a HF prevalence of 4.4% (95% confidence
interval [CI]: 3.7 to 5.0%) in individuals older than 25 years [6].
A higher prevalence was observed in the older population, which
may indicate that, due to the population ageing in recent decades,
the current and future prevalence of HF in Portugal may be
higher [7].
A recent burden of disease study estimated that HF accounts
for 5% of the total deaths in mainland Portugal and for more than
20,000 disability-adjusted life years (DALY) [8]. Over the next two
decades, as the population ages, the burden of HF, measured in
DALY, and the number of deaths due to HF are expected to
increase by 28% and 73%, respectively [8]. Furthermore, the HF
burdenhas a significant economic impact in Portugal, estimated to
be equivalent to 2.6% of the total public health expenditure [9].
The current recommended first-line treatments for patients
with heart failure with reduced ejection fraction (HFrEF) with
prior or current symptoms are angiotensin converting enzyme
inhibitors (ACEI) or angiotensin receptor blockers (ARB) com-
bined with a beta-blocker and a diuretic, as needed [10]. These
agents have been shown to be cost-effective and in certain
cases, besides reducing cardiovascular morbidity and mortality,
are also cost-saving options [11–14].
Sacubitril/valsartan, a first-in-class angiotensin receptor nepri-
lysin inhibitor (ARNI), is an innovative therapeutic option for the
treatment of HFrEF. In the pivotal clinical trial, PARADIGM-HF,
sacubitril/valsartan showed clinically relevant and statistically
significant reduction in cardiovascular mortality and HF hospita-
lization after 27 months compared with enalapril (hazard ratio
[HR] of 0.80, 95% CI, 0.73 to 0.87; p-value<0.001) [15]. In fact,
sacubitril/valsartan is already recommended in the most recent
guidelines for the treatment of patients with symptomatic HFrEF
(New York Heart Association [NYHA] class II-IV) who tolerate an
ACEI or ARB [10].
This study assesses the cost-effectiveness of sacubitril/
valsartan, for the treatment of patients with HFrEF with
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NYHA class II-IV, compared to enalapril, in Portugal, adopt-
ing the societal perspective.
2. Methods
A previously developed Markov model [16] using patient-level
data from the PARADIGM-HF trial [15] was adapted to the
Portuguese setting.
The model considers two health states (alive or dead) and uses
regression analyses to estimate hospitalizations and deaths over
time. The model is based on predictive sub-models of cardiovas-
cular mortality, hospitalization rate, and QoL, according to the
treatment each patient receives and their clinical and demo-
graphic characteristics at baseline (Figure 1). This is a cohort
based model which is run using the baseline characteristics –
and associated risks – of each patient in turn and the resulting
outcomes recorded. Costs and outcomes are obtained for the
cohort of patients as a whole by averaging individual costs and
outcomes for all patients. The decision analytic model was con-
structed in MS® Excel®.
The simulation was run with one-month cycles, with half-
cycle correction. Full details of the model have been reported
previously [16].
Enalapril was chosen as the comparator not only because it was
the active comparator in the PARADIGM-HF trial but also because
the European Society of Cardiology (ESC) recommends the inclu-
sion of an ACEI in the treatment of HFrEF and the Portuguese
Society of Cardiology adopts the ESC guidelines [15,17].
Due to the absence of national data, the patient population
was obtained from the PARADIGM-HF trial, i.e., adult patients with
HFrEF and NYHA class II-IV, which in turn is the same population
considered in sacubitril/valsartan label [15,18]. Detailed baseline
characteristics are presented in Supplementary Table 1.
The societal perspective was adopted assuming a 30-year time
horizon, during which all patients were expected to be dead. An
annual 5% discount rate was used for costs and consequences
occurring after one year. This is aligned with the current
Portuguese guidelines for health economic studies [19].
2.1. Model inputs
2.1.1. Clinical data and health related quality of life
Cardiovascular mortality, hospitalization rates, QoL, and
adverse events (AE) were obtained from the PARADIGM-HF
trial [15,16]. Details of the predictive sub-models used have
been reported previously [16].
The cardiovascular mortality curve was estimated from the
PARADIGM-HF data using the Gompertz parametric distribution
to extrapolate beyond the duration of the trial. The Gompertz
model resulted in a HR of 0.81 (95% CI: 0.72 to 0.90;
p-value<0.001) for sacubitril/valsartan versus enalapril, which is
consistent with the primary statistical analysis of the PARADIGM-
HF (HR 0.80, 95% CI: 0.71 to 0.89; p-value<0.001). Details of the
Gompertz model are presented in Supplementary Table 2.
Cardiovascular mortality depends on the treatment arm,
patients’ baseline characteristics, and time since randomization.
The effect of hospitalization rates and AE rates on cardiovascular
mortality is implicitly included in the trial data [15,16].
The non-cardiovascular mortality was estimated using
the official Portuguese life tables by sex and age [20],
adjusted to remove cardiovascular mortality. General and
cardiovascular mortality in the Portuguese population was
obtained from the Health Statistics 2013, published by
Statistics Portugal [21]. Cardiovascular deaths were identi-
fied using the code LES – 33 (Diseases of the circulatory
system). Cardiovascular mortality rates were converted into
annual probabilities, assuming a constant risk. It was also
assumed that the probability of death was constant in the
5-year age groups provided by Statistics Portugal. This
probability of cardiovascular death was then subtracted
from the general mortality in the life tables, resulting in
the non-cardiovascular mortality.
The all-cause hospitalizations rate was also estimated from
the PARADIGM-HF data using a negative binomial regression
model permitting extrapolation beyond the end of the trial.
The proportion of each hospitalization type is applied to estimate
the number of HF, cardiovascular (non-HF) and non-cardiovas-
cular hospitalizations experienced over the time horizon. These
proportions are assumed to be constant over time. Details of the
negative binomial regression model are presented in
Supplementary Table 3.
Utility values were estimated using a mixed-effects model
based on the treatment arm, baseline characteristics (including
baseline EQ-5D), hospitalizations, AE, and time since randomiza-
tion [16]. Supplementary Table 4 summarizes the results of the
mixed-effects model. In addition to the differences in utilities
between sacubitril/valsartan and enalapril due to differences in
hospitalization rate and AE, sacubitril/valsartan was also asso-
ciated with a small but statistically significant positive effect on
EQ-5D, compared with enalapril, after adjusting for baseline
characteristics, hospitalization, AE and time. Utilities used in the
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Figure 1. Conceptual model (based on McMurray et al., 2018 [16]).
Legend: QALYs, quality-adjusted life years.
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base-case scenario include this additional benefit of sacubitril/
valsartan. Also, the analysis of EQ-5D data suggested a utility
decrease of 0.008 (95% CI: 0.006 to 0.009) across both arms over
the duration of the PARADIGM-HF trial (median follow-up of
27 months). In the absence of long-term EQ-5D data in patients
with HFrEF, the base-case analysis assumed a constant decline in
EQ-5D over the model’s time horizon.
As it is expected that severe AE are included in hospitalizations
resources, the model considered only non-severe AE, particularly
those pre-specified in the PARADIGM-HF trial which included
hypotension, increase in serum creatinine, hyperkalemia, cough,
and angioedema [15]. These AE were modeled assuming
a constant incidence for each, as AE were assumed to have little
impact on cost-effectiveness results (low cost, low incidence, and
low impact on patients’ QoL). AE incidence and mean duration
were obtained from PARADIGM-HF (Supplementary Table 5) [15].
2.1.2. Costs
The following costs were considered: costs with therapy, HF
management, inpatient care, medical visits and AE.
Pharmacological therapy costs were obtained from the
National Authority of Medicines and Health Products
(INFARMED) database (Infomed) from 2016 [22]. The cost of sacu-
bitril/valsartan and enalapril was based on the average doses
taken in the PARADIGM-HF trial (enalapril, 18.9 mg/day and sacu-
bitril/valsartan, 375 mg/day) [15]. Sacubitril/valsartan costs asso-
ciated with titration consisted of two general medical practice
visits. The standard therapy combined with either sacubitril/val-
sartan or enalapril included beta-blockers, diuretics, aldosterone
antagonists, and digoxin. Additionally, due to the high usage
observed in the PARADIGM-HF trial, anticoagulants, aspirin, ade-
nosine diphosphate antagonists, and lipid lowering therapies
were also considered. To estimate the standard therapy cost, the
defined daily dose (DDD) was used and the dosage and package
with the lowest price per mg were considered. The aggregated
monthly cost of standard therapy, weighted by the percentage of
patients whowere taking it (based on the PARADIGM-HF trial [15]),
was estimated at 11.7 €. Other non-pharmacological therapy costs,
such as implantable cardioverter-defibrillators, were considered to
be included in the hospitalization and ambulatory costs.
To estimate resource consumption with hospitalizations, the
National Health System 2014 Diagnosis related groups (DRG)
Database was used [23]. According to the International
Classification of Diseases, 9th Revision Clinical Modification (ICD-
9-CM), hospitalization episodes with the code 428.x (Heart Failure)
were identified in anydiagnosis. Of the episodes identifiedwithHF,
those with a DDX1 (primary diagnosis) or a procedure code listed
in Supplementary Table 6 were selected. The average unit cost of
a HF patient hospitalization was estimated at 2,600 €, by summing
the products of the number of episodes in each selected DRG and
their respective price, defined in the national legislation (Order
234/2015) [23,24].
The unit costs of health resources (medical visits, emergency
episodes, and HF management) were obtained from national
legislation (Order 234/2015) and their respective literature
sources are detailed in Supplementary Table 7 [24].
A panel of Portuguese HF experts was undertaken to over-
come the lack of information on resource consumption in the
ambulatory setting. Experts were asked to give an estimation
of the annual cost for the first and the following years with the
disease (Table 1).
Given that the model does not permit a different cost for the
first year and the following years, a value reflecting the average
cost of the average life expectancy was estimated. Considering
a mean survival of 6.5 years for a HFrEF patient (mean undis-
counted life years of patients in sacubitril/valsartan and enalapril
arms), an average monthly cost of 24 € was calculated for the
healthcare resources consumed in the ambulatory setting (for
both patients in sacubitril/valsartan and enalapril).
The healthcare resources consumption in the treatment of AE
associatedwithHFwas defined by a panel of United Kingdom (UK)
experts and validated by three of the Portuguese experts. Experts
informed on the additional medical visits, medication, emergency
room visits, blood tests or other health resources needed in the
occurrence of an AE. Total cost per AE was calculated summing up
the costs of the additional health resources identified (Table 2).
2.2. Sensitivity analysis
One-way deterministic sensitivity analyses were performed to
test the robustness of the findings and evaluate the impact of
uncertainty, considering alternative assumptions for key para-
meters in the model. Additional sensitivity analysis varying mod-
el’s assumptions and modeling options were explored. The
robustness of results was also assessed by probabilistic sensitivity
analyses in which a total of 1,000 simulations were run.
3. Results
3.1. Base case analysis
Sacubitril/valsartan therapy potentially leads to an increased
life expectancy of 0.52 life years (LY) when compared to
enalapril. These health gains correspond to an incremental
QALY of 0.44 versus enalapril (Table 3).
The total incremental cost difference between sacubitril/val-
sartan and enalapril was 10,021 € (Table 3). The most substantial
cost difference was associated with the cost of primary drug
Table 1. Costs of healthcare resource consumption in the ambulatory setting
obtained from the expert panel.
Annual cost,
1st year
Annual cost,
following years
Medical visits, specialty 82 € 41 €
Medical visits, GP 78 € 76 €
Emergency room episodes (with no
hospitalization)
92 € 42 €
Ambulance 15 € 8 €
Background medical management 164 € 97 €
Total 432 € 263 €
Legend: GP, general practice.
Table 2. Cost per adverse event.
Adverse event Cost
Hypotension 62 €
Cough 67 €
Angioedema 89 €
Serum creatinine increase 63 €
Hyperkalemia 64 €
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therapy, which was partially offset by the reduction in hospitali-
zation costs (−543 €).
The incremental cost-effectiveness ratio (ICER) for sacubitril/
valsartan versus enalapril was 22,702 € per QALY gained (Table 3).
3.2. Deterministic sensitivity analysis
Scenario analyses were performed in which key structural
assumptions were varied and ICERs reported. A total of 119
parameters were evaluated in the one-way sensitivity analysis.
Results were robust in most scenarios (maximum ICER of 36,059
€/QALY), showing greater sensitivity to the parameters estimates
of the cardiovascular survival curve (Figure 2). In fact, variations in
the cardiovascular survival curve were the only scenarios tested
with ICERs exceeding 30,000 €/QALY.
Additional sensitivity analyses were explored in which model
assumptions or modeling options were altered. Table 4 shows
the main results of this analysis. Results were robust but sensi-
tive to the costs and consequences discount rate (19,465
€/QALY when both costs and consequences discount rates are
0%) and when no additional benefit in patients’ QoL with
sacubitril/valsartan is assumed (27,065 €/QALY). Changes in
other parameters or assumptions such as NYHA class, prior
treatment with ACEI or ARB, 50% reduction in hospitalization
costs, costs of sacubitril/valsartan and enalapril according to
their targeted doses, among others, had no significant impact
on the ICER (Table 4).
When an older population of patients was considered
(mean = 67 years), in line with the mean age of the sample
in the EPICA study [6], and when the western European
subgroup of patients in the PARADIGM-HF trial was also con-
sidered, an ICER of 20,534 €/QALY was obtained, showing the
robustness of results to this parameter.
Results were sensitive to the time horizon. Nevertheless,
sacubitril/valsartan remained cost-effective in a time horizon
of 10 years with an ICER of 29,458 €/QALY.
3.3. Probabilistic sensitivity analysis
The cost-effectiveness scatterplot (Figure 3) shows that all
simulations are in the northeast cost-effectiveness quadrant,
showing that sacubitril/valsartan is more effective but costlier
than enalapril. The estimated average probabilistic ICER was
24,281 €/QALY.
According to the probabilistic sensitivity analysis, 74% of the
simulations resulted in an ICER <30,000€/QALY, the commonly
accepted cost-effectiveness threshold in Portugal (Figure 4).
4. Discussion
HF is a global public health problem, with a high prevalence and
social impact [1]. Despite the efficacy of therapeutic options
available prior to the introduction of sacubitril/valsartan, there
was undoubtedly a need to obtain greater benefits in terms of
mortality and hospitalizations reduction, and signs and symp-
toms relief. Sacubitril/valsartan, a new treatment option for
patients with HFrEF, showed clinically relevant and statistically
significant reduction in mortality and hospitalizations [15].
The current cost-effectiveness study is the result of the adap-
tation of a previously developed model for the Portuguese rea-
lity, in which the cost-effectiveness of sacubitril/valsartan is
compared with that of enalapril [16].
The base case results showed that besides its clinical benefit,
sacubitril/valsartan also brings additional costs. However, com-
pared to enalapril and given the commonly accepted Portuguese
cost-effectiveness willingness-to-pay threshold of 30,000 €/QALY,
sacubitril/valsartan is estimated to be cost-effectivewith an ICER of
22,702 €/QALY. This result was mainly driven by a reduction in
mortality and hospitalizations and by an improvement in QoL.
Table 3. Base case cost-effectiveness results estimated over lifetime (30 years),
discounted.
Sacubitril/valsartan Enalapril Δ
LY 6.71 6.19 0.52
QALY 5.09 4.65 0.44
Total costs 19,949 € 9,928 € 10,021 €
ICER 22,702 €/QALY
Legend: Δ, difference; ICER, incremental cost-effectiveness ratio; LY, life years;
QALY, quality-adjusted life years.
Figure 2. Tornado diagram with the 10 parameters that most influenced the ICER.
Legend: coef., coefficient; CV, cardiovascular; ICER, incremental cost-effectiveness ratio.
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These results were robust to a range of sensitivity analyses, includ-
ing the use of different sources for all-cause mortality, and a more
advanced mean patient age. These analyses also showed that
results were independent of disease severity or prior treatment
with an ACEI or ARB which is representative of the Portuguese
reality given that the reimbursed population are patients with
HFrEF, NYHA II-III, and prior treatment for at least four weeks with
an ACEI or ARB.
Comparison of these results with other countries is difficult
due to country-specific information. Nevertheless, these findings
are consistent with other recently published cost-effectiveness
analyses in which sacubitril/valsartan is suggested to be a cost-
effective option for the treatment of HFrEF [16,25–30]. All studies
reported an increase in life years with sacubitril/valsartan in all
simulated populations. In the United States (US), sacubitril/val-
sartan demonstrated good value for money at the current accep-
table threshold, with an ICER of 47,053 $/QALY [30]. Likewise, in
the UK, Colombia, and Denmark, sacubitril/valsartan was pro-
jected to yield cost-effectiveness ratios as low as 11,200 €/QALY
(Colombia) and as high as 22,600 €/QALY (Denmark) when com-
pared to enalapril, which are below the accepted cost-
effectiveness thresholds in each country [16]. In Germany,
although cost-effectiveness analyses have no formal role in reim-
bursement and pricing of new pharmaceuticals, sacubitril/valsar-
tan yielded an ICER of 26,278 €/QALY, which is at or below the
ratio of other accepted interventions for the treatment of HF [25].
Additionally, an Italian study concluded that sacubitril/valsartan
is a cost-effective option with an ICER of 19,487 €/QALY (below
the usually accepted willingness-to-pay threshold of 40,000
€/QALY in Italy) [28]. Differences in results between US and
European studies are mainly due to differences in costs (i.e. the
US has higher treatment and hospitalization costs [30]). For
example, whereas in Portugal there is an increased cost of
10,021 € with sacubitril/valsartan versus enalapril, in the US, the
incremental cost is $ 29,203 [30].
This analysis is associated with some limitations. First, the
clinical effectiveness of sacubitril/valsartan was based on a single
clinical trial (PARADIGM-HF) that was stopped early due to
a cardiovascular mortality benefit versus enalapril [15]. Also, the
study population in the PARADIGM-HFwas geographically diverse
and may not fully represent the Portuguese patients. As cost-
effectiveness is dependent on patients’ absolute risk of events,
which is dependent on patients’ baseline clinical characteristics,
cost-effectiveness results may differ if PARADIGM-HF and
Portuguese patients’ characteristics do not align.
The adaptation of this model to the Portuguese reality con-
sisted of using specific country input data whenever available. For
non-cardiovascular mortality, Portuguese life tables were used.
However, these data assumed that the non-cardiovascular health
of a HF patient is similar to that of the general population. This
may be inaccurate given that HF patients suffer from several
comorbidities that may increase their risk of non-cardiovascular
Table 4. Scenario analyses results.
Sensitivity analysis ICER
Base-case 22,702 €/QALY
No additional benefit of sacubitril/valsartan in utilities 27,065 €/QALY
Western Europe patients 25,325 €/QALY
All-cause mortality using data from PARADIGM-HF 24,248 €/QALY
Increase in non-CV mortality: SMR = 2 (instead of 1)a 23,931 €/QALY
Sacubitril/valsartan and enalapril costs according to
target doses
23,351 €/QALY
50% reduction in hospitalization costs 23,317 €/QALY
Baseline NYHA class III/IV 22,967 €/QALY
Prior use of ACEI 22,873 €/QALY
Baseline NYHA class I/II 22,631 €/QALY
Prior use of ARB 22,131 €/QALY
Discount rate (costs and consequences) = 0 19,465 €/QALY
Legend: ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor
blockers; CV, cardiovascular; ICER, incremental cost-effectiveness ratio; NYHA,
New York Heart Association classification; QALY, quality-adjusted life years; SMR,
standardizedmortality ratio. a standardized mortality ratios (SMR) are implemented
in a scenario analysis such that non-cardiovascular mortality is increased by 100% in
both model arms.
Figure 3. Cost-effectiveness scatterplot (1,000 simulations).
Legend: QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio.
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mortality. To overcome this limitation, sensitivity analyses were
run with the following changes: an increase in the non-
cardiovascular mortality by the application of different standar-
dized mortality ratios ([SMR]; SMR = 2, ICER 23,931 €/QALY) and
the utilization of the PARADIGM-HF data as the source of mortality
for all causes (ICER 24,248 €/QALY). These results reinforced the
robustness of the model.
Finally, despite being common practice in many cost-
effectiveness analyses, one of the major limitations of this study
is the extrapolation of sacubitril/valsartan clinical outcomes
beyond the PARADIGM-HF observation period. To address this,
the long-term effects of treatment assumptions on mortality, QoL,
and all-cause hospitalizations were examined by performing sen-
sitivity analyses. Model results were most sensitive to the cardio-
vascularmortality and the hospitalizations curve; however, no ICER
was above 36,059 €/QALY. As expected, results were sensitive to
shorter time horizons as the greater benefit of sacubitril/valsartan
is attributable to increased survival (for instance, for a time horizon
of 10 years the ICER obtained was 29,458 €/QALY).
Several strengths of the current study should be noted. Firstly,
patient-level data from the PARADIGM-HF [15] trial were used to
predict cardiovascular mortality, all-cause hospitalization, and
health-related QoL. This provided a high level of internal consis-
tency as well as the opportunity to incorporate heterogeneity
between patients in the model. Another strength was the way
EQ-5D results were used and analyzed in themodel. EQ-5D scores,
from the PARADIGM-HF trial, were modelled using amixed effects
model, which takes into consideration time trends observed in the
trial rather than a single point in time [16].
5. Conclusions
Sacubitril/valsartan offers good value for money in the treat-
ment of Portuguese patients with chronic heart failure with
reduced ejection fraction, at a willingness-to-pay threshold of
30,000 €. Moreover, this innovative therapy has a favorable
impact on patients’ morbidity and mortality.
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